Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hypopituitarism screening and growth hormone treatment after subarachnoid hemorrhage
NL-OMON23702Recruiting
- Sponsor
- Erasmus MC
- Start
- Jun 2009
- Modality
- Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Open-label trial of somatropin and human ghrelin in hypopituitarism and growth hormone deficiency (GHD) (3 arms), sponsored by Erasmus MC. Primary endpoints: Incidence of hypopituitarism after subarachnoid hemorrhage and Risk factors for hypopituitarism after subarachnoid hemorrhage. Started Jun 2009; status: recruiting.
02
Drugs
somatropinhuman ghrelin
03
Conditions
hypopituitarismgrowth hormone deficiency (GHD)
Beyond the preview
Go deeper on NL-OMON23702.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON23702.